骨髄増殖性疾患治療薬の世界市場レポート 2025年

骨髄増殖性疾患治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.3％で117億3,000万米ドルに成長します。予測期間の成長は、高齢化、精密医療の進歩、新規治療法の出現、希少疾患への世界の注目、政府の取り組み、ヘルスケア政策などに起因すると考えられます。予測期間における主な動向としては、精密医療へのアプローチ、治験治療薬の臨床試験、症状管理の改善、ルキソリチニブの使用拡大、疾患バイオマーカーの重視などが挙げられます。

骨髄増殖性疾患の増加が予想されることから、これらの疾患に対処する薬剤市場の成長が見込まれます。骨髄増殖性疾患は急性白血病とは異なり、1つまたは複数の血球系における異常な細胞増殖を伴う。この増加は主に、遺伝的要因、放射線や化学物質などの環境暴露、人口の高齢化に起因しています。骨髄増殖性疾患の治療薬は、BCR-ABLタンパク質をブロックし、下流のリン酸化プロセスを阻害することによって作用し、治療を助ける。特に、2022年8月の国立衛生研究所によると、慢性骨髄性白血病は男性に多く、10万人当たりの新規発症率は女性の1.4人に対し約2.4人であり、市場成長の原動力となっています。

骨髄増殖性疾患治療薬市場は、研究開発投資の増加によって大きな影響を受けると予想されます。このような投資とは、商業的利益を見込んで、製品開発のための新しい知識の発見と応用を推進するために企業が行う財政的コミットメントを指します。このような投資は、骨髄増殖性疾患治療薬の強力なパイプラインを見れば明らかなように、新規治療法の革新に向けて行われています。特に、2023年9月の国立科学技術統計センターによると、連邦政府による研究開発費は2020年度から2021年度にかけて13.6％（227億米ドル）急増し、過去最高の1,902億米ドルに達し、骨髄増殖性疾患治療薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界骨髄増殖性疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の骨髄増殖性疾患治療薬市場：成長率分析
• 世界の骨髄増殖性疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界の骨髄増殖性疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界骨髄増殖性疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨髄増殖性疾患治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性骨髄線維症
• 真性多血症（PV）
• 本態性血小板血症（ET）
• 慢性好酸球性白血病または高好酸球症候群（HES）
• 全身性肥満細胞症（SM）
• 世界の骨髄増殖性疾患治療薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• JAK2阻害剤
• 抗腫瘍薬
• 脱メチル化剤
• イマチニブメシル酸塩
• その他の薬物の種類
• 世界の骨髄増殖性疾患治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の骨髄増殖性疾患治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売店
• ドラッグストア
• 世界の骨髄増殖性疾患治療薬市場、原発性骨髄線維症のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• JAK阻害剤
• 免疫調節剤
• 支持療法
• 世界の骨髄増殖性疾患治療薬市場真性多血症（PV）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• JAK阻害剤
• ヒドロキシウレア
• 瀉血
• インターフェロンアルファ
• 世界の骨髄増殖性疾患治療薬市場、本態性血小板血症（ET）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• JAK阻害剤
• ヒドロキシウレア
• アナグレリド
• インターフェロンアルファ
• 世界の骨髄増殖性疾患治療薬市場慢性好酸球性白血病または高好酸球症候群（HES）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤
• コルチコステロイド
• インターフェロンアルファ
• 世界の骨髄増殖性疾患治療薬市場全身性肥満細胞症（SM）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤
• コルチコステロイド
• 抗ヒスタミン薬
• 免疫療法

第7章 地域別・国別分析

• 世界の骨髄増殖性疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨髄増殖性疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨髄増殖性疾患治療薬市場：競合情勢
• 骨髄増殖性疾患治療薬市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Incyte Corporation
• Eli Lilly and Co
• F Hoffmann-La Roche Ltd.
• Mylan NV
• Fresenius Kabi AG
• Hikma Pharmaceuticals plc
• GSK plc
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International Gmbh
• Sanofi Aventis Inc.
• AstraZeneca AB
• Apotex Inc
• Celgene Co.
• Gamida Cell Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨髄増殖性疾患治療薬市場2029：新たな機会を提供する国
• 骨髄増殖性疾患治療薬市場2029：新たな機会を提供するセグメント
• 骨髄増殖性疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myeloproliferative disorder drugs encompass medications used to address blood cancers arising from stem cell alterations within the bone marrow, the critical site for blood cell production. These drugs target various types of blood malignancies, including myelodysplastic/myeloproliferative disorders.

The primary categories of myeloproliferative disorder drugs include primary myelofibrosis, polycythemia vera (PV), essential thrombocythemia (ET), chronic eosinophilic leukemia or hyper eosinophilic syndrome (HES), and systemic mastocytosis (SM). Primary myelofibrosis refers to an uncommon chronic blood condition characterized by abnormal synthesis of fibrous tissue in the bone marrow, leading to reduced blood cell production and the formation of scar tissue. These drugs belong to categories such as JAK2 inhibitors, anti-neoplastic agents, demethylation agents, imatinib mesylate, and others. They can be administered orally, parenterally, or through other means. Distribution channels include hospital pharmacies, retail outlets, and drug stores.

The myeloproliferative disorders drugs market research report is one of a series of new reports from The Business Research Company that provides myeloproliferative disorders drugs market statistics, including myeloproliferative disorders drugs industry global market size, regional shares, competitors with a myeloproliferative disorders drugs market share, detailed myeloproliferative disorders drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myeloproliferative disorders drugs industry. This myeloproliferative disorders drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myeloproliferative disorders drugs market size has grown steadily in recent years. It will grow from$9.47 billion in 2024 to $9.92 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increased incidence of myeloproliferative disorders, advancements in understanding disease mechanisms, clinical research and drug development, improvements in diagnosis and screening, patient advocacy and awareness

The myeloproliferative disorders drugs market size is expected to see steady growth in the next few years. It will grow to $11.73 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to aging population, advancements in precision medicine, emergence of novel therapies, global focus on rare diseases, government initiatives and healthcare policies. Major trends in the forecast period include precision medicine approaches, clinical trials for investigational therapies, improved symptom management, expanded use of ruxolitinib, focus on disease biomarkers.

The anticipated increase in myeloproliferative disorders is poised to drive the growth of the market for drugs addressing these conditions. Myeloproliferative disorders, distinct from acute leukemia, entail abnormal cellular growth in one or more blood cell lines. This rise is chiefly attributed to genetic factors, environmental exposures such as radiation or chemicals, and the aging population. Medications for myeloproliferative diseases act by blocking the BCR-ABL protein, hindering downstream phosphorylation processes, thereby aiding in their treatment. Notably, according to the National Institute of Health in August 2022, chronic myelogenous leukemia was more prevalent in men, with an incidence rate of approximately 2.4 new cases per 100,000 compared to 1.4 new cases per 100,000 in women, signifying the driving force behind the market's growth.

The trajectory of the myeloproliferative disorders drug market is expected to be significantly influenced by increased investments in research and development. Such investments refer to the financial commitments made by companies to drive the discovery and application of new knowledge for product development, anticipating commercial gain. These investments are channeled towards innovating novel treatments, evident in the robust pipeline of drugs for myeloproliferative disorders. Notably, as per the National Center for Science and Engineering Statistics in September 2023, federal commitments for research and experimental development surged by 13.6% ($22.7 billion) from FY 2020 to FY 2021, reaching an all-time high of $190.2 billion, fostering growth in the myeloproliferative disorders drug market.

Product innovation stands as a prominent trend shaping the landscape of myeloproliferative disorder drugs. Key industry players are dedicated to crafting novel products to fortify their market standing. For instance, in September 2023, GSK plc announced FDA approval for momelotinib to treat primary myelofibrosis, a myeloproliferative disorder. This medication, momelotinib, operates uniquely by blocking three crucial signaling pathways activin A receptor type I (ACVR1), Janus kinase (JAK) 1, and JAK2. Its inhibition of JAK1 and JAK2 can potentially alleviate splenomegaly and other symptoms associated with the disorder, while also reducing hepcidin levels, known to contribute to anemia in myelofibrosis.

Major players in the myeloproliferative disorder drugs market are strategically focusing on introducing and obtaining approvals for advanced drug solutions, aiming to gain a competitive edge. The introduction and approval of these innovative drug solutions significantly enhance the availability of advanced therapies for patients grappling with myeloproliferative disorders. Notably, in September 2023, Novartis AG disclosed the National Institute for Health and Care Excellence's (NICE) approval for Jakavi (ruxolitinib), a JAK 1/2 inhibitor sanctioned for treating polycythaemia vera (PV). This approval grants access to Ruxolitinib for eligible patients in England and Wales, addressing an unmet treatment need as a substantial percentage of patients under existing therapies develop resistance or intolerance. PV, a subtype of myeloproliferative disorder, poses serious health risks and leads to approximately 1,130 new diagnoses per year in the UK.

In May 2022, Merk, a renowned biopharmaceutical firm based in the US, completed the acquisition of Imago BioSciences Inc. for $1.35 billion. This strategic acquisition is anticipated to bolster Merk's standing as a key player in clinical development, leveraging Imago BioSciences' expertise. Particularly, it aims to optimize the therapeutic potential of bomedemstat, an LSD1 inhibitor, and Imago's pipeline. Additionally, this move reinforces Merk's foothold in the expanding field of hematology. Imago BioSciences, a US-based clinical-stage biopharmaceutical company, specializes in the discovery and development of groundbreaking medications aimed at treating myeloproliferative neoplasms.

Major companies operating in the myeloproliferative disorders drugs market include Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Incyte Corporation, Eli Lilly and Co, F Hoffmann-La Roche Ltd., Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals plc, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International Gmbh, Sanofi Aventis Inc., AstraZeneca AB, Apotex Inc, Celgene Co., Gamida Cell Ltd., Geron Co., Promedior Inc., Johnson & Johnson Private Limited, AbbVie Inc., AOP Orphan Pharmaceuticals AG, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Chemical Pharma Co. Ltd., Eisai Pharmaceuticals India Pvt. Ltd.

North America was the largest region in the myeloproliferative disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the myeloproliferative disorders drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The myeloproliferative disorder drugs market consists of sales of jasatinib, nilotinib, jakafi, hydroxyurea, and gleevec. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myeloproliferative Disorders Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myeloproliferative disorders drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myeloproliferative disorders drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myeloproliferative disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Primary Myelofibrosis; Polycythemia Vera (PV); Essential Thrombocythemia (ET); Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES); Systemic Masto cytosis (SM)
• 2) By Drug Type: JAK2 Inhibitors; Anti-Neoplastics; Demethylation Agents; Imatinib Mesylate; Other Drug Types
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Stores; Drug Stores
• Subsegments:
• 1) By Primary Myelofibrosis: JAK Inhibitors; Immunomodulatory Agents; Supportive Care
• 2) By Polycythemia Vera (PV): JAK Inhibitors; Hydroxyurea; Phlebotomy; Interferon-alpha
• 3) By Essential Thrombocythemia (ET): JAK Inhibitors; Hydroxyurea; Anagrelide; Interferon-alpha
• 4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors; Corticosteroids; Interferon-alpha
• 5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors; Corticosteroids; Antihistamines; Immunotherapy
• Companies Mentioned: Novartis AG; Bristol-Myers Squibb Company; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myeloproliferative Disorders Drugs Market Characteristics

3. Myeloproliferative Disorders Drugs Market Trends And Strategies

4. Myeloproliferative Disorders Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Myeloproliferative Disorders Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myeloproliferative Disorders Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myeloproliferative Disorders Drugs Market Growth Rate Analysis
• 5.4. Global Myeloproliferative Disorders Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myeloproliferative Disorders Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myeloproliferative Disorders Drugs Total Addressable Market (TAM)

6. Myeloproliferative Disorders Drugs Market Segmentation

• 6.1. Global Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Myelofibrosis
• Polycythemia Vera (PV)
• Essential Thrombocythemia (ET)
• Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES)
• Systemic Masto cytosis (SM)
• 6.2. Global Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JAK2 Inhibitors
• Anti-Neoplastics
• Demethylation Agents
• Imatinib Mesylate
• Other Drug Types
• 6.3. Global Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Myeloproliferative Disorders Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Stores
• Drug Stores
• 6.5. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Primary Myelofibrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JAK Inhibitors
• Immunomodulatory Agents
• Supportive Care
• 6.6. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Polycythemia Vera (PV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JAK Inhibitors
• Hydroxyurea
• Phlebotomy
• Interferon-alpha
• 6.7. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Essential Thrombocythemia (ET), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JAK Inhibitors
• Hydroxyurea
• Anagrelide
• Interferon-alpha
• 6.8. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Corticosteroids
• Interferon-alpha
• 6.9. Global Myeloproliferative Disorders Drugs Market, Sub-Segmentation Of Systemic Mastocytosis (SM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Corticosteroids
• Antihistamines
• Immunotherapy

7. Myeloproliferative Disorders Drugs Market Regional And Country Analysis

• 7.1. Global Myeloproliferative Disorders Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myeloproliferative Disorders Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myeloproliferative Disorders Drugs Market

• 8.1. Asia-Pacific Myeloproliferative Disorders Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myeloproliferative Disorders Drugs Market

• 9.1. China Myeloproliferative Disorders Drugs Market Overview
• 9.2. China Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myeloproliferative Disorders Drugs Market

• 10.1. India Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myeloproliferative Disorders Drugs Market

• 11.1. Japan Myeloproliferative Disorders Drugs Market Overview
• 11.2. Japan Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myeloproliferative Disorders Drugs Market

• 12.1. Australia Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myeloproliferative Disorders Drugs Market

• 13.1. Indonesia Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myeloproliferative Disorders Drugs Market

• 14.1. South Korea Myeloproliferative Disorders Drugs Market Overview
• 14.2. South Korea Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myeloproliferative Disorders Drugs Market

• 15.1. Western Europe Myeloproliferative Disorders Drugs Market Overview
• 15.2. Western Europe Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myeloproliferative Disorders Drugs Market

• 16.1. UK Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myeloproliferative Disorders Drugs Market

• 17.1. Germany Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myeloproliferative Disorders Drugs Market

• 18.1. France Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myeloproliferative Disorders Drugs Market

• 19.1. Italy Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myeloproliferative Disorders Drugs Market

• 20.1. Spain Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myeloproliferative Disorders Drugs Market

• 21.1. Eastern Europe Myeloproliferative Disorders Drugs Market Overview
• 21.2. Eastern Europe Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myeloproliferative Disorders Drugs Market

• 22.1. Russia Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myeloproliferative Disorders Drugs Market

• 23.1. North America Myeloproliferative Disorders Drugs Market Overview
• 23.2. North America Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myeloproliferative Disorders Drugs Market

• 24.1. USA Myeloproliferative Disorders Drugs Market Overview
• 24.2. USA Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myeloproliferative Disorders Drugs Market

• 25.1. Canada Myeloproliferative Disorders Drugs Market Overview
• 25.2. Canada Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myeloproliferative Disorders Drugs Market

• 26.1. South America Myeloproliferative Disorders Drugs Market Overview
• 26.2. South America Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myeloproliferative Disorders Drugs Market

• 27.1. Brazil Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myeloproliferative Disorders Drugs Market

• 28.1. Middle East Myeloproliferative Disorders Drugs Market Overview
• 28.2. Middle East Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myeloproliferative Disorders Drugs Market

• 29.1. Africa Myeloproliferative Disorders Drugs Market Overview
• 29.2. Africa Myeloproliferative Disorders Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myeloproliferative Disorders Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myeloproliferative Disorders Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myeloproliferative Disorders Drugs Market Competitive Landscape And Company Profiles

• 30.1. Myeloproliferative Disorders Drugs Market Competitive Landscape
• 30.2. Myeloproliferative Disorders Drugs Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Myeloproliferative Disorders Drugs Market Other Major And Innovative Companies

• 31.1. Incyte Corporation
• 31.2. Eli Lilly and Co
• 31.3. F Hoffmann-La Roche Ltd.
• 31.4. Mylan NV
• 31.5. Fresenius Kabi AG
• 31.6. Hikma Pharmaceuticals plc
• 31.7. GSK plc
• 31.8. Bayer AG
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Boehringer Ingelheim International Gmbh
• 31.11. Sanofi Aventis Inc.
• 31.12. AstraZeneca AB
• 31.13. Apotex Inc
• 31.14. Celgene Co.
• 31.15. Gamida Cell Ltd.

32. Global Myeloproliferative Disorders Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myeloproliferative Disorders Drugs Market

34. Recent Developments In The Myeloproliferative Disorders Drugs Market

35. Myeloproliferative Disorders Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Myeloproliferative Disorders Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myeloproliferative Disorders Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myeloproliferative Disorders Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer